Human DT-diaphorase as a candidate for enzyme-directed bioreductive drug development

Drugs of the Future

Volumn 21, Issue 12, 1996, Pages 1247-1256

  Phillips, Roger M ^a  

^a UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 5 (1 AZIRIDINYL) 3 HYDROXYMETHYL 2 (3 HYDROXY 1 PROPENYL) 1 METHYL 4,7 INDOLEDIONE; DIAZIQUONE; MITOMYCIN C; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); RUFOCROMOMYCIN;

ANTINEOPLASTIC ACTIVITY; DRUG ACTIVATION; DRUG DEVELOPMENT; ENZYME ACTIVITY; HUMAN; NONHUMAN; REVIEW; SPECIES DIFFERENCE; TUMOR CELL;

EID: 0030513844     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (130)

1. Thomlinson, R.H., Gray, L. H. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1958, 9: 539-49.
2. Kennedy, K.A, Hypoxic cells as specific drug targets for chemotherapy. Anti-Cancer Drug Des 1987, 2: 181-94.
3. Sartorelli, A.C. Therapeutic attack of hypoxic cells of solid tumours: Presidential address. Cancer Res 1988, 48: 775-8,
4. Vaupel, P., Kallinowski, F., Okunieff, P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumours: A review. Cancer Res 1989, 49: 6449-65.
5. Workman, P., Stratford, I.J. The experimental development of bioreductive drugs and their role in cancer therapy. Cancer Metastasis Rev 1993, 12: 73-82.
6. Brown, J.M., Garcia, A.J. Tumour hypoxia: The picture has changed in the 1990s. Int J Radiat Biol 1994, 65: 95-102.
7. Lin, A.J., Cosby, L.A., Shansky, C.W., Sartorelli, A.C. Potential bioreductive alkylating agents. Benzoquinone derivatives. J Med Chem1972, 15: 1247-52.
8. Workman, P., Wallon, M.I. Enzyme directed bioreductive drug development. In: Selective Activation of Drugs by Redox Processes. Adams, G.E., Breccia, A., Fielden, E.M., Wardman, P. (Eds.). Plenum Press: New York 1990, 173-91.
9. Ernster, L., Navazio, F. Soluble diaphorases in animal tissues. Acta Chem Scand 1958, 12: 595.
10. Ernster, L. DT-diaphorase: A historical review. Chem Scripta 1987, 27A: 1-13.
11. Lind, C., Cadenas, E., Hochstein, P., Ernster, L. DT-diaphorase: Purification, properties and function. Methods Enzymol 1990,186: 287-301.
12. Riley, R.J., Workman, P. DT-diaphorase and cancer chemotherapy. Biochem Pharmacol 1992, 43: 1657-99.
13. Ross, D., Siegel, D., Beall, H., Prakash, A.S., Mulcahy, R.T., Gibson, N.W. DT-diaphorase in activation and detoxification of quinones. Bioreductive activation ofmitomycin C. Cancer Metastasis Rev 1993, 12:83-101.
14. Ross, D., Beall, H., Traver, R.D., Siegel, D., Phillips, R.M., Gibson, N.W. Bioactivation of quinones by DT-diaphorase, molecular, biochemical and chemical studies. Oncol Res 1994, 6: 493-500.
15. Joseph, P., Xie, T., Xu, Y., Jaiswal, A.K. NAD(P)H:quinone oxidoreductase-1 (DT-diaphorase): Expression, regulation and role in cancer. Oncol Res 1994. 6: 525-32.
16. Workman, P. Enzyme directed bioreductive drug development revisited: A commentary on recent progress and future prospects with emphasis on quinone anticancer agents and quinone metabolising enzymes, particularly DT-diaphorase. Oncol Res 1994, 6: 461-75.
17. Ross, D., Beall, H.D., Siegel, D., Traver, R.D., Gustafson, D.L. Enzymology of bioreductive drug activation. Br J Cancer 1996, 74 (Suppl. 27): S1-9.
18. Cadenas, E. Antioxidant and prooxidant functions of DT-diaphorase in quinone metabolism. Biochem Pharmacol 1995, 49: 127-40.
19. Wallin, R., Rammels, S.R., Martin, L.F. DT-diaphorase and vitamin K dependent carboxylases in liver and in macrophages and type II endothelial cells isolated from rat lung. Chem Scripta 1987, 27A: 193-202.
20. Suttie, J.W. Vitamin K-dependent carboxylase. Ann Rev Biochem 1985, 54: 459-77.
21. Talcott, R.E., Rosenblum, M., Levin, V.A. Possible role of DT-diaphorase in the bioactivation of antitumour quinones. Biophys Res Commun 1983, 111: 346-51.
22. DeFlora, S., Bernnicelli, C., Camoirano, A., Serra, D., Hochstein, P. Influence of DT-diaphorase on the mutagenicity of organic and inorganic compounds. Carcinogenesis 1988, 9: 611-7.
23. Beyer, R.E., Segura-Aguilar, J., Dibernardo, S. et al. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proc Natl Acad Sci USA 1996, 93: 2528-32.
24. Powis, G. Metabolism and reactions of quinoid anticancer agents. In: Anticancer Drugs: Reactive Metabolism and Drug Interactions. Powis, G. (Ed.). Pergamon Press: Oxford 1994, 273-352.
25. Rauth, A.M., Marshall, R.S., Kuehl, B.L. Cellular approaches to bioreductive drug mechanisms. Cancer Metastasis Rev 1993, 12: 153-64.
26. Smilkamp-Wilms, E., Hendriks, H.R., Peters, G.J. Development, pharmacology, role of DT-diaphorase and prospects of the indoloquinone EO9. Gen Pharmacol 1996, 27: 421-9.
27. Workman, P. Keynote address: Bioreductive mechanisms. Int J Radiat Oncol Biol Phys 1992, 22: 631-7.
28. Smitkamp-Wilms, E., Giaccone, G., Pinedo, H.M., Van der Laan, B.F.A.M., Peters, G.F. DT-diaphorase activity in normal and neoplastic human tissues: An indicator for sensitivity to bioreductive agents? Br J Cancer 1995, 72: 917-21.
29. Traver, R.T., Horikoshi, T., Dannenberg, K.D. et al. NAD(P)H:quinone oxidoreductase gene expression in human colon carcinoma cells: Characterisation of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 1992, 52: 797-802.
30. Smitkamp-Wilms, E., Peters, G.F., Pinedo, H.M., Van Ark-Otte, J., Giaccone, G. Chemosensitivity to the indoloquinone EO9 is correlated with DT-diaphorase activity and its gene expression. Biochem Pharmacol 1994, 47: 1325-32.
31. Horikoshi, T., Dannenberg, K.D., Stadibauer, T.H.W, et al. Quantitation of thymidylate synthase, dihydrofolate reductase and DT-diaphorase gene expression in human tumours using the polymerasechain reaction. Cancer Res 1992, 52: 108-16.
32. Eickelmann, P., Schulz, W.A., Rohde, D., Schmitz-Drager, B., Sies, H. loss of heterozygosity at the NAD(P)H:quinone oxidoreductase locus associated with increased resistance against mitomycin C in a human bladder carcinoma cell line. Biol Chem HoppeSeyler 1994, 375: 439-45.
33. Gasdaska, P.Y., Fisher, H., Powis, G. An alternatively spliced form of NQO1 (DT-diaphorase) messenger RNA lacking the putative quinone substrate binding site is present in human normal and tumour tissues. Cancer Res 1995, 55: 2542-7.
34. Yao, K-S., Godwin, A.K., Johnson, C.,O'Dwyer, P.J. Alternative splicing and differential expression of DT-diaphorase transcripts in human colon tumours and in peripheral mononuclear cells in response to mitomycin C treatment. Cancer Res 1996, 56: 1731 -6.
35. Murray, G.I., Burke, M.D. Immunohistochemistry of drug metabolising enzymes. Biochem Pharmacol 1995, 50: 895-903.
36. Segura-Aguilar, J., Cremades, A., Llombart-Bosh, A., Monsalve, E., Ernster, L., Romero, F.J. Activity and immunohistochemistry of DT-diaphorase in hamster and human kidney tumours. Carcinogenesis 1994, 15: 1631-6.
37. Fitzsimmons, S.A., Workman, P., Grever, M., Paull, K., Camalier, R., Lewis, A.D. Reductase enzyme express/on across the National Cancer Institute tumor cell line panel: Correlation with sensitivity to mitomycin C and EO9. J Natl Cancer Inst 1996, 88: 259-69.
38. Malkinson, A.M., Siegel, D, Forrest, G.L. et al. Elevated DT-diaphorase activity and messenger RNA content in human non-small cell lung carcinoma: Relationship to the response of lung tumour xenografts to mitomycin C. Cancer Res 1992, 52: 4752-7.
39. Robertson, N., Haigh, A., Adams, O.E., Stratford, I.J. Factors affecting sensitivity to EO9 in rodent and human tumour cells in vitro: DT-diaphorase activity and hypoxia. Eur J Cancer 1994,30A: 1013-9.
40. Belinsky, M., Jaiswal, A.K. NAD(P)H:quinone oxidoreductase 1 (DT-diaphorase) expression in normal and tumour tissues. Cancer Met Rev 1993, 12: 103-17.
41. Schlager, J.J., Powis, G. Cytosolic NAD(P)H:(quinone acceptor) oxidoreductase in human normal and tumour tissue: Effects of cigarette smoking and alcohol. Int J Cancer 1990, 45: 403-9.
42. Cresteil, T., Jaiswal, A.K. High levels of expression of the NAD(P)H:quinone oxidoreductase (NQO1) gene in tumour cells compared to normal cells of the same origin. Biochem Pharmacol 1991, 42: 1021-7.
43. Schor, N.A., Cornelisse, C.J. Biochemical and quantitative histochemical study of reduced pyridine nucleotide dehydrogenation by human colonic carcinomas. Cancer Res 1983, 43: 4850-5.
44. Berger, M.S., Talcott, R.E., Rosenblum, M.L., Suva, M., AliOsman, F., Smith, M.T. The use of quinones in brain tumour chemotherapy. Preliminary results from preclinical investigations. J Toxicol Environ Health 1985, 16: 713-9.
45. Jarren, C.M., Clayton, M.R.K., Bibby, M.C., Phillips, R.M. DT-diaphorase activity in malignant and normal lung, ovarian and gastric tissues. Br J Cancer 1996, 73 (Suppl. 26): 34.
46. Gasdaska, P.Y., Powis, G., Hyman, P., Fisher, H. Cigarette smoking is a determinant of DT-diaphorase gene expression in human non small cell lung carcinoma. Cancer Res 1993, 53: 5458-61.
47. Eickelmann, P., Ebert, T., Warskulat, U., Schultz, W.A., Sies, H. Expression of NAD(P)H:quinone oxidoreductase and glutathione S-transferases a and it in human renal cell carcinoma and in kidney cancer derived cell lines. Carcinogenesis 1994, 15: 219-25.
48. O'Dwyer, P.J., Yao, K-S., Ford, P., Godwin, A.K., Clayton, M. Effects of hypoxia on detoxicating enzyme activity and expression in HT-29 colon adenocarcinoma cells. Cancer Res 1994, 54: 3082-7.
49. Yao, K-S., O'Dwyer, P.J. Involvement of NF-κB in the induction of NAD(P)H:quinone oxidoreductase (DT-diaphorase) by hypoxia. oltipraz and mitomycin C. Biochem Pharmacol 1995, 49: 275-82.
50. Phillips, R.M., de la Cruz, A., Gibson, N.W. Relationship between DT-diaphorase activity and chemosensitivity in vitro to analogues of mitomycin C and diaziquone. Br J Cancer 1994, 69 (Suppl. 21): 59.
51. Plumb, J.A., Workman, P. Unusually marked hypoxic sensitisation to indoloquinone EO9 and mitomycin C in a human colon tumour cell line that lacks DT-diaphorase activity. Int J Cancer 1994, 56: 134-9.
52. Schlager, J.J., Hoert, B.J., Riebow, J. et al. Increased NAD(P)H:(quinone acceptor) oxidoreductase activity is associated with density dependent growth inhibition of normal but not transformed cells. Cancer Res 1993, 53: 1338-42.
53. Martius, C. Ouinone reductases. The Enzymes, Vol. 7. Boyer, P.D., Lardy, H., Myrback, K. (Eds.). Academic Press: New York 1963, 517-32.
54. Keuhl, B.L, Paterson, J.W.E., Peacock, J.W., Paterson, M.C., Rauth, A.M. Presence of a heterozygous substitution and its relationship to DT-diaphorase activity. Br J Cancer 1995, 72: 555-61.
55. Lewis, A.D., Holyoake, T.L, Dunlop, D.J., Pragnell, I.D., Workman, P. Lack of myelosuppression with EO9 in human and mouse bone marrow: Correlation with low DT-diaphorase activity. Proc Am Assoc Cancer Res 1993, 34: 345.
56. Siegel, D., Ross, D. NAD(P)H:quinone oxidoreductase(DT-dia-phorase) activity in human bone marrow stroma. Role in quinone induced cytotoxicity. Proc Am Assoc Cancer Res 1996, 37: 290.
57. Oostveen, E.A., Speckamp, W.N. Mitomycin analogues 1. Indoloquinones as potent bisalkylating agents. Tetrahedron 1987, 43: 255-62.
58. Walton, M.I., Smith, P.J., Workman, P. The role of NAD(P)H:quinone reductase (EC 1.6.99.2, DT-diaphorase) in the reductive bioactivation of the novel indoloquinone antitumour agent EO9. Cancer Commun 1991, 3: 199-206.
59. Walton, M.I., Sugget, N., Workman, P. The role of human and rodent DT-diaphorase in the reductive metabolism of hypoxic cell cytotoxins. Int J Radiat Oncol Biol Phys 1992, 22: 643-7.
60. Beall, H.D., Murphy, A.M., Siegel, D., Hargreaves, R.H.J., Butler, J., Ross, D. Nicotinamide adenine dinucleotide (phosphate): Quinone oxidoreductase (DT-diaphorase) as a target for antitumour quinones: Quinone cytotoxicity and selectivity in human lung and breast cancer cell lines. Mol Pharmacol 1995, 48: 499-504.
61. Collard, J., Matthew, A.M., Double, J.A., Bibby, M.C. EO9:Relationship between DT-diaphorase levels and response in vitro and in vivo. Br J Cancer 1995, 71: 1199-203.
62. Robertson, N., Stratford, I.J., Houlbrook, S., Carmichael, J., Adams, G.E. The sensitivity of human tumour cells to quinone bioreductive drugs: What role for DT-diaphorase? Biochem Pharmacol 1992, 44: 409-12.
63. Plumb, J.A., Gerntsen, M., Workman, P. DT-diaphorase protects cells from the hypoxic cytotoxicity of indoloquinone EO9. Br J Cancer 1994, 70: 1136-43.
64. Gustafson, D.L., Beall, H.D., Bolton, E.M., Waldren, C.A., Ross. D. Effects of NQ01 (DT-diaphorase) expression on antitumour quinone cytotoxicity in CHO cells. Proc Am Assoc Cancer Res 1996, 37: 357-8.
65. Begleiter, A., Leith, M.K., Curphey, T.J. Induction of DT-diaphorase by 1,2-dithiole-3-thione and increase of antitumour activity of bioreductive agents. Br J Cancer 1996, 74 (Suppl. 27): S9-14.
66. Bailey, S.M., Lewis, A.D., Patterson, L.H., Fisher, G.R., Work-man. P. Free radical generation following reduction of EO9: Involvement in cytotoxicity. Br J Cancer 1993, 67 (Suppl. 20): 8.
67. Butler, J., Spanswick, V.J., Cummings, J. The autooxidation of the reduced forms of E09. Free Rad Res 1996, 25: 141-8.
68. Spanswick, V.J., Butler, J., Cummings, J.,Smyth, J. The molecular pharmacology of indoloquinone EO9. Br J Cancer 1996, 73 (Suppl. 26): 28.
69. Maliepaard, M., Wolf, A., Groot, S.E., de Mol, N.J., Janssen, L.H.M. Indoloquinone EO9: DNA interstrand cross linking upon reduction by DT-diaphorase orxanthine oxidase. Br J Cancer 1995, 71: 836-9.
70. Bailey, S.M., Lewis, A.D., Workman, P. Involvement of NADPH:cytochrome P450 reductase in activation of EO9. Br J Cancer 1994, 59 (Suppl. 21): 57.
71. Saunders, M., Jaffar, M., Patterson, A.V. et al. Structural requirements for E09 toxicity and dependence on P450 reductase for activation. Br J Cancer 1996, 73: 27.
72. Roed, H., Aabo, K., Vindelov, L., Spang-Thomsen, M., Christensen, I.J., Hansen, H.H. In vitro and in vivo evaluation of the indoloquinone EO-9 (NSC 382459) against human small cell carcinoma of the lung. Eur J Cancer 1989, 25: 1197-201.
73. Hendriks, H.R., Piazo, P.E., Berger, O.P. et al. EO9: A novel bioreductive atkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur J Cancer 1993, 29A: 897-906.
74. Wallon, M.I., Bibby, M.C., Double, J.A., Plumb, J.A., Workman, P. DT-diaphorase activity correlates with sensitivity to the indoloquinone EO9 in mouse and human colon carcinomas. Eur J Cancer 1992, 28A: 1597-600.
75. Adams, G.E., Stratford, I.J., Edwards, H.S., Bremner, J.C.M., Cole, S. Bioreductive drugs as postirradiation sensitizers: Comparison of dual function agents with SR4233 and the mitomycin C analogue EO9. Int J Radiat Oncol Biol Phys 1992, 22: 717-20.
76. Kal, H.B., Karim, A.B.M.F., Hendriks, H.R. The efficacy of E09 with radiation in experimental rat tumours. Ann Oncol 1994, 5: 88.
77. Wanders, J., Pavlidis, N., Gamucci, T. et al. Phase II studies with EO9in breast, colorectal, gastric, pancreatic and NSCLC. Eur J Cancer 1995, 31A (Suppl. 5): 565.
78. Schellens, J.H.M., Planting, A.S.T., van Acker, B.A.C. et al. Phase I and pharmacologic study of the novel indoloquinone bioreductive alkylating cytotoxic drug EO9. J Natl Cancer Inst 1994, 86: 906-12.
79. McLeod, H.L., Graham, M.A., Aamdal, S., Setanoians, A., Groot, Y., Lund, B. Phase I pharmacokinetics and limited sampling strategies for the bioreductive alkylating drug EO9. Eur J Cancer 1996, 32A: 1518-22.
80. Bibby, M.C., Cronin, B.P., Phillips, R.M. Evaluation of the cytotoxicity of the indoloquinone EO9 in a human colon adenocarcinoma model Int J Oncol 1993, 3: 661-6.
81. Sartorelli, A.C., Hodnick, W.F., Belcourt, M.F. et al. Mitomycin C: A prototype bioreductive agent. Oncol Res 1994, 6: 501-8.
82. Keyes, S.R., Fracasso, P.M., Heimbrook, D.C., Rockwell, S., Sligar, S.G., Sartorelli, A.C. Role of NADPH:cytochrome c reductase and DT-diaphorase in the biotransformation of mitomycin C. Cancer Res 1984, 44: 5638-43.
83. Keyes, S.R., Rockwell, S., Sartorelli, A.C. Enhancement of mitomycin cytotoxicity to hypoxic tumour cells by dicoumarol in vivo and in vitro. Cancer Res 1985, 45: 213-6.
84. Rockwell, S., Keyes, S.R., Sartorelli, A.C. Modulation of the cytotoxicity of mitomycin C to EMT6 mouse mammary tumour cells by dicoumarol in vitro. Cancer Res 1988, 48: 5471-4.
85. Marshall, R.S., Paterson, M.C., Rauth, A.M. Deficient activation by a human cell strain leads to mitomycin resistance under aerobic but not hypoxic conditions. Br J Cancer 1989, 59: 341-6.
86. Schlager, J.J., Powis, G. Mitomycin C is not metabolised by but is an inhibitor of human kidney NAD(P)H: (quinone acceptor) oxidoreductase. Cancer Chemother Pharmacol 1988, 22: 126-30.
87. Workman, P., Walton, M.I., Powis, G., Schlager, J.J. DT-diaphorase: Questionable role in mitomycin C resistance, but a target for novel bioreductive drugs. Br J Cancer 1989, 60: 800-2.
88. Siegel, D., Beall, H., Kasai, M., Gibson, N.W., Ross, D. pH dependent inactivation of DT-diaphorase by mitomycin C and porfiromycin. Mol Pharmacol 1993, 44: 1128-34.
89. Siegel, D., Gibson, N.W., Preusch, P.C., Ross, D. Metabolism of mitomycin C by DT-diaphorase: Role in mitomycin C induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 1990, 50: 7483-9.
90. Siegel, D., Beall, H., Senekowitsch, C. et al. Bioreductive activation of mitomycin C by DT-diaphorase. Biochemistry 1992, 31: 7878-85.
91. Prakash, A.S., Beall, H.D., Ross, D., Gibson, N.W. Sequence selective alkylation and cross linking induced by mitomycin C upon activation by DT-diaphorase. Biochemistry 1993, 32: 5518-25.
92. Begleiter, A., Leith, M.K. Role of NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under acidic conditions. Mol Pharmacol 1993, 44: 210-5.
93. Kennedy, K.A., McGrul, J.D., Leondaridis, L., Alabaster, O. pH dependence of mitomycin C induced cross linking activity in EMT6 tumour cells. Cancer Res 1985, 45: 3541-7.
94. Pan, S-S., Yu, F., Hipsher, C. Enzymatic and pH modulation of mitomycin C induced DNA damage in mitomycin C resistant HCT 116 human colon cancer cells. Mol Pharmacol 1993, 43: 870-7.
95. Griffiths, J.R. Are cancer cells acidic? Br J Cancer 1991, 64: 425-7.
96. Phillips, R.M., de la Cruz, A., Gibson, N.W. Relationship between DT-diaphorase activity and chemosensitivity in vitro to analogues of mitomycin C and diaziquone. Br J Cancer 1994, 69 (Suppl. 21): 59.
97. Dulhanty, A.M., Whitmore, G.F. Chinese hamster ovary cells resistant to mitomycin C under aerobic but not hypoxic conditions are deficient in DT-diaphorase. Cancer Res 1991, 51: 1860-5.
98. Marshall, R.S., Paterson, M.C., Rauth, A.M. DT-diaphorase and mitomycin C sensitivity in nontransformed cell strains derived from members of a cancer prone family. Carcinogenesis 1991, 12: 1175-1180.
99. Kasahara, K., Shibata, K., Bando, T., Numata, Y., Fujimura, M., Matsuda, T. DT-diaphorase as determinant of sensitivity to adriamycin in non-small cell lung cancer cell lines. Int J Cancer 1994, 59: 204-7.
100. O'Dwyer, P.J., Perez, R.P., Yao, K-S., Godwin, A.K., Hamilton, T.C. Increased DT-diaphorase expression and cross resistance to mitomycin C in a series of cisplatin resistant human ovarian cancer cell lines. Biochem Pharmacol 1996, 52: 21-7.
101. Belcourt, M.F., Hodnick, W.F., Rockwell, S., Sartorelli, A.C. Bioactivation of mitomycin antibiotics and hypoxic Chinese hamster ovary cells overexpressing DT-diaphorase. Biochem Pharmacol 1996, 51: 1669-78.
102. Mikami, K., Naito, M., Tomida, A., Yamada, M., Sirakusa, T., Tsuruo, T. DT-diaphorase as a critical determinant of sensitivity to mitomycin C in human colon and gastric cell lines. Cancer Res 1996, 56: 2823-6.
103. Powis, G., Gasdaska, P.Y., Gallegos, A., Sherrill, K., Goodman, D. Over expression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone drug sensitivity: A questionable role for the enzyme as a target for bioreductively activated anticancer drugs. Anticancer Res 1995, 15: 1141-6.
104. Beall, H.D., Mulcahy, T., Siegel, D., Traver, R.D., Gibson, N.W., Ross, D. Metabolism of bioreductive antitumour compounds by purified rat and human DT-diaphorases. Cancer Res 1994, 54: 3196-201.
105. Begleiter, A., Robotham, E., Leith, M.K. Role of NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under hypoxia. Mol Pharmacol 1992, 41: 677-82.
106. Belcourt, M.F., Hodnick, W.F., Rockwell, S., Sartorelli, A.C. Differential toxicity of mitomycin Cand porfiromycin to aerobic and hypoxic Chinese hamster ovary cells over expressing human NADPH:cytochrome c (P450) reductase. Proc Natl Acad Sci USA 1996, 93: 456-60.
107. Hodnick, W.F., Sartorelli, A.C. Reductive activation of mitomycin C by NADH:cytochrome b5 reductase. Cancer Res 1993, 53: 4907-12.
108. Gustafson, D.L., Pritsos, C.A. Bioactivation of mitomycin C by xanthine dehydrogenase from EMT6 mouse mammary carcinoma tumours. J Natl Cancer Inst 1992, 84: 1180-5.
109. Pritsos, C.A., Gustafson, D.L. Xanthine dehydrogenase and its role in cancer chemotherapy. Oncol Res 1994, 6: 477-82.
110. Pan, S., Andrews, P., Glover, C., Bachur, N.R. Reductive activation of mitomycin C and mitomycin C metabolites by NADPH cytochrome P450 reductase and xanthine oxidase. J Biol Chem 1984, 259: 959-66.
111. Pritsos, C.A., Pardini, L.L., Elliot, A.J., Pardini, R.S. Relation-ship between antioxidant enzyme DT-diaphorase and tumour response to mitomycin C treatment. In: Oxygen Radicals in Biology and Medicine. Simic, M.G., Taylor, K.A., Ward, J.F., Von Sonntag, C. (Eds.). Plenum Press: New York 1989, 713-6.
112. Khan, A.H., Driscoll, J.S. Potential central nervous system antitumour agents aziridinylbenzoquinones 1. J Med Chem 1976, 19: 313-7.
113. Maral, J., Poisson, M., Pertuiset, B.F. et al. Phase II evaluation of diaziquone (Cl-904, AZQ) in the treatment of human malignant glioma. J Neuro-Oncol 1985, 3: 245-9.
114. Siegel, D., Gibson, N.W., Preusch, P.C., Ross, D. Metabolism of diaziquone by NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): Role in diaziquone induced DNA damage and cytotoxicity in human colon carcinoma cells. Cancer Res 1990, 50: 7293-300.
115. Gibson, N.W., Hartley, J.A., Butler, J., Siegel, D., Ross, D. Relationship between DT-diaphorase mediated metabolism of a series of aziridinylbenzoquinones and DNA damage and cytotoxicity. Mol Pharmacol 1992, 42: 531-6.
116. Lee, C.-S., Hartley, J.A., Berardini, M.D. et al. Alteration in DNA cross linking and sequence selectivity of a series of aziridinylbenzoquinones after enzymatic reduction by DT-diaphorase. Biochemistry 1992, 31: 3019-25.
117. Berardini, M.D., Souhami, R.L, Lee, C.-S., Gibson, N.W., Butler, J., Hartley, J.A. Two structurally related diaziridinylbenzoquinones preferentially cross link DNA at different sites upon reduction with DT-diaphorase. Biochemistry 1993, 32: 3306-12.
118. Cummings, J., Langdon, S.P., Ross,D., Butler, J. Antitumour activity of the novel bioreductive MeDZQ against human non-small cell lung cancer xenografts. Ann Oncol 1996, 7 (Suppl. 1): 129.
119. Beall, H.D., Liu, Y., Siegel, D., Bolton, E.M., Gibson, N.W., Ross, D. Role of NAD(P)H:quinone oxidoreductase (DT-diaphorase) in cytotoxicity and induction of DNA damage by streptonigrin. Biochem Pharmacol 1996, 51: 645-52.
120. Cone, R., Hasan, S.K., Lown, J.W., Morgan, A.R. Themechanism of the degradation of DNA by streptonigrin. Can J Biochem 1976, 54: 219-23.
121. Bachur, N.R., Gordon, S.L, Gee, M.V., Kon, H. NADPH:cytochrome P450 reductase activation of quinone anticancer agents to free radicals. Proc Natl Acad Sci USA, 1979, 76: 954-7.
122. Boland, M.P., Knox, R.J., Roberts, J.J. The differences in kinetics of rat and human DT-diaphorase results in a differential sensitivity of derived cells to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). Biochem Pharmacol 1991, 41: 867-75.
123. Williams, J.B., Lu, A.Y.H., Cameron, R.G., Pickett, C.B. Rat liver NAD(P)H:quinone reductase. J Biol Chem 1986, 261: 5524-8.
124. Jaiswal, A.K., McBride, D.W., Adensik, M., Nebert, D.W. Human dioxin inducib/e cytosolic NAD(P)H:quinone oxidoreductase. J Biol Chem 1988, 263: 13572-8.
125. Chen, S., Clarke, P.E., Martino, P.A. et al. Mouse liver NAD(P)H:quinone acceptor oxidoreductase: Protein sequence and analysis by tandem mass spectrometry, cDNA cloning, expression in E. coli and enzyme activity analysis. Protein Sci 1994, 3: 1296-304.
126. Chen, S., Knox, R., Lewis, A.D. et al. Catalytic properties of NAD(P)H:quinone acceptor oxidoreductase: Studies involving mouse, rat, human and mouse-rat criimeric enzymes. Mol Pharmacol 1995, 47: 934-9.
127. Phillips, R.M., Bibby, M.C., Double, J.A. A critical appraisal of the predictive value of in vitro chemosensitivity assays. J Natl Cancer Inst 1990, 82: 1457-68.
128. Gardiner, J., Ritchie, A.A., Cummings, J., Jodrell, D.I., Smyth, J. Encapsulation of the indoloquinone EO9 as a potential therapy for the treatment of colorectal liver metastases. Br J Cancer 1996, 73 (Suppl. 26): 28.
129. Phillips, R.M. The bioreductive activation of a series of potential based anti-cancer drugs by human DT-diaphorase. Ann Oncol 1996, 7 (Suppl. 1): 376.
130. Bailey, S.M., Sugget, N., Walton, M.I., Workman, P. Structure activity relationships for DT-diaphorase reduction of hypoxic cell directed agents: Indoloquinones and diaziridinyl benzoquinones. Int J Radiat Oncol Biol Phys 1992, 22: 649-53.